Related Experiment Videos

New-onset diabetes and antihypertensive therapy: comments on ALLHAT trial

Cristina Sierra1, Luis M Ruilope

  • 1Hypertension Units, Hospital Clinic of Barcelona, Madrid, Spain.

Journal of the Renin-Angiotensin-Aldosterone System : JRAAS
|November 11, 2003
PubMed

Insights

Certain blood pressure medications increase the risk of new-onset diabetes in hypertensive patients. Diuretics and beta-blockers are linked to higher risks, while other classes show lower risks.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • New-onset diabetes is a common complication in patients with hypertension undergoing treatment.
  • The risk of developing diabetes varies significantly based on the antihypertensive medication used.

Purpose of the Study:

  • To investigate the association between different classes of antihypertensive drugs and the incidence of new-onset diabetes.
  • To compare the diabetogenic potential of various antihypertensive therapies.

Main Methods:

  • Analysis of patient data from the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
  • Comparison of new-onset diabetes prevalence across different treatment groups.

Main Results:

  • Diuretics and beta-blockers were associated with a higher prevalence of new-onset diabetes.
  • Calcium channel blockers, ACE inhibitors, and ARBs showed a lower prevalence, even when combined with diuretics.

Conclusions:

  • Antihypertensive medication choice impacts the risk of developing new-onset diabetes.
  • Further long-term studies are needed to fully understand the clinical significance of new-onset diabetes in treated hypertensive individuals.

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Thiazide-Class Diuretics01:15

Antihypertensive Drugs: Thiazide-Class Diuretics

Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...